Experienced in Plasmacytoma

Dr. Julian R. Sprague

Hematology | Oncology
University Of Vermont Medical Center Inc
111 Colchester Ave, 
Burlington, VT 
Accepting New Patients
Experienced in Plasmacytoma
University Of Vermont Medical Center Inc
111 Colchester Ave, 
Burlington, VT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julian Sprague is a Hematologist and an Oncologist in Burlington, Vermont. Dr. Sprague is rated as an Experienced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Autoimmune Hemolytic Anemia, Large-Cell Immunoblastic Lymphoma, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sprague is currently accepting new patients.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in VT
Hospital Affiliations
The University Of Vermont Health Network-Alice Hy
Northwestern Medical Center Inc
Champlain Valley Physicians Hospital Medical Ctr
Univ. Of Vermont - Fletcher Allen Health Care
Copley Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UNIVERSITY OF VERMONT MEDICAL CENTER INC
111 Colchester Ave, Burlington, VT 05401
Other Locations
UNIVERSITY OF VERMONT MEDICAL CENTER INC
1 S Prospect St, Burlington, VT 05401

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
Managed Access Program (MAP) Cohort Treatment Plan CBYL719F12001M to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Managed Access Program (MAP) Cohort Treatment Plan CBYL719F12001M to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Enrollment Status: Available
Publish Date: October 28, 2024
Intervention Type: Drug
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Enrollment Status: Completed
Publish Date: December 01, 2021
Intervention Type: Drug, Radiation
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Study Phase: Phase 2
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2021
Intervention Type: Drug, Procedure
Study Drugs: Carmustine, Cytarabine, Etoposide, Thiotepa, Granulocyte Colony-Stimulating Factor
Study Phase: Phase 2
View 5 Less Clinical Trials

10 Total Publications

B-Lymphoblastic Leukemia with BCR::ABL1-like Features After Long-term Lenalidomide Therapy.
B-Lymphoblastic Leukemia with BCR::ABL1-like Features After Long-term Lenalidomide Therapy.
Journal: Journal of the Association of Genetic Technologists
Published: December 06, 2024
Similar Doctors
Experienced in Plasmacytoma
Dr. Eric A. Pillemer
Hematology Oncology | Oncology
Experienced in Plasmacytoma
Dr. Eric A. Pillemer
Hematology Oncology | Oncology

University Of Vermont Medical Center Inc

111 Colchester Ave, 
Burlington, VT 
 (0.1 miles away)
802-847-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Pillemer is a Hematologist Oncology specialist and an Oncologist in Burlington, Vermont. Dr. Pillemer is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Hairy Cell Leukemia (HCL), Neuroendocrine Tumor, and Paget Disease of the Breast.

Experienced in Plasmacytoma
Dr. Jose M. Acostamadiedo
Hematology Oncology | Oncology | Hematology
Experienced in Plasmacytoma
Dr. Jose M. Acostamadiedo
Hematology Oncology | Oncology | Hematology

Champlain Valley Physicians Hospital Medical Center

75 Beekman St, 
Plattsburgh, NY 
 (20.4 miles away)
518-561-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jose Acostamadiedo is a Hematologist Oncology specialist and an Oncologist in Plattsburgh, New York. Dr. Acostamadiedo is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sprague's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 37 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile